
    
      The Investigators have designed a one-arm phase II prospective sequential clinical trial to
      assess the therapeutic efficacy of 177-Lu-[DOTA 0, Tyr 3] octreotate (177-Lu- DOTATATE)
      applied intravenously in three separate doses to patients with inoperable progressive WDNET.
    
  